Engineered probiotic combines local chemotherapy and immunotherapy in mouse tumours
A peer-reviewed Science Translational Medicine study engineered E. coli Nissle 1917 to activate chemotherapy and release two immune therapies inside tumours. The system produced local and systemic antitumour effects in mouse colorectal and melanoma models, but there is no human efficacy or safety evidence.